Cannabinoid-based tablet will be used in the upcoming first clinical trial in its program for the treatment of cognitive impairments

“The completion of the formulation phase is one of the Company’s targets for 2016, and its achievement advances the Company towards the commencement of the first clinical trial, which is expected to begin in North American in the beginning of 2017”[Canadian Friends of The Hebrew University of Jerusalem]

Therapix Biosciences, a pharma company specializing in the development and commercialization of cannabinoid-based drugs, on Tuesday announced the successfully completion of the development phase of a unique formulation of a tablet for sublingual administration for pharmaceutical use. The tablet is expected to be used in the context of a clinical trial for treatment of impairments in cognitive functioning (including mild cognitive impairment that could result in Alzheimer’s disease), towards which Therapix is currently preparing.In June 2016, the Company entered into a binding memorandum of understandings with Belvit, a Swiss drug development company, for the receipt of a worldwide and exclusive license to use a formulation for sublingual administration of ultra-low dosages of THC (the active ingredient in cannabis), for the purpose of developing and marketing the formulation in the indications on which the Company has chosen to focus, with an emphasis on treatment of cognitive impairments.According to some scientific literature, sublingual administration of THC in the designated formulation, is superior and more efficient than oral administration.

Dr. Elran Haber, Therapix’s CEO, said that Therapix continues to realize its business strategy in the research and development of cannabinoid-based drugs.

“The completion of the formulation phase is one of the Company’s targets for 2016, and its achievement advances the Company towards the commencement of the first clinical trial, which is expected to begin in North America in the beginning of 2017,” Dr. Haber said.

About Therapix

Therapix is an Israeli pharma company specializing in the development and commercialization of approved drugs that are based on cannabinoid molecules. The Company is listed on the Tel Aviv Stock Exchange and is also traded over-the counter (OTC) in the United States. The Company is engaged in the development of a drug based on cannabinoids and the entourage technology for treating Tourette syndrome, and is preparing for the development of a cannabinoid-based drug for treating impairments in cognitive functioning (including preliminary stages of Alzheimer’s disease).

The company’s stock jumped by 16.85 percent back in 2014 when it acquired medical cannabis developer Lara Pharm Ltd., which is developing a formulation of THC to work in an inhaler.

Archives

Facebook bans me often! Join the Toke Signals emaillist.

Join the email list to be notified when I post new articles. Since Facebook routinely bans me for little or no reason, this is the best way to stay up to date with Uncut, Uncensored, No Holds Barred, Non Corporate Controlled Cannabis News.

Thanks for subscribing! One more step: Please check your email and click the link to verify your email address.